NCT02269280View on ClinicalTrials.gov

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

October 13, 2014

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
Leukemia
Interventions
DRUG

Azacitidine (AZA) Days 1 - 3

Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.

DRUG

Decitabine (DAC)

Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.

OTHER

Best Supportive Care (BSC)

Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.

DRUG

Azacitidine (AZA) Days 1 - 5

Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.

Trial Locations (6)

10065

NYP/Weill Cornell Medical Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic Foundation, Cleveland

77030

M D Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02269280 - Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter